TEL AVIV Teva Pharmaceutical Industries is counting on
its new migraine treatment to haul it out of the doldrums.
TEL AVIV, May 2 (Reuters)- Teva Pharmaceutical Industries is counting on
its new migraine treatment to haul it out of the doldrums.
TEL AVIV, May 2 - Teva Pharmaceutical Industries is counting on
its new migraine treatment to haul it out of the doldrums.
Not exact matches
Migraine is a debilitating disorder affecting around 1 in 7 people worldwide, but its molecular mechanisms remain poorly understood which makes developing
new treatments challenging.
«If approved, this
treatment would provide physicians with an important
new tool to help prevent
migraine, reduce a patient's
migraine load, and potentially help patients return to normal» says Dr. Silberstein.
Clinicians at Albany Medical Center and the State University
New York Empire State College in Saratoga Springs used a
treatment called image - guided, intranasal sphenopalatine ganglion (SPG) blocks to give patients enough ongoing relief that they required less medication to relieve
migraine pain.
«People with
migraine are looking for non-drug
treatments, and this
new device is easy to use, has no side effects and can be conveniently used in work or social settings.»
For
treatment, that knowledge could make a huge impact: not only should researchers be better about testing potential
migraine drugs on men and women separately, Maleki says, but they may be able to design
new treatments based on these brain differences — giving both sexes a better chance at relief.
«We hope this review of medical
treatments will serve as a guide for doctors and patients on how to interpret
new findings, especially regarding four
treatment options that doctors have commonly used for their pregnant patients with
migraines,» said Rebecca Erwin Wells, M.D., assistant professor of neurology at Wake Forest Baptist and lead author of the paper.
Dr. Oren Tessler, Assistant Professor of Clinical Surgery at LSU Health Sciences Center
New Orleans School of Medicine, is part of a team of plastic and reconstructive surgeons who report a high success rate using a method to screen and select patients for a specific surgical
migraine treatment technique.
Amgen's pipeline has struggled for several years but its
new cholesterol drug Repatha and upcoming launches for osteoporosis and
migraine treatments could prove blockbusters.
He was the global leader for product development and commercialization activities for LY2951742 — Lilly's novel CGRP neutralizing antibody — a
new potential
treatment for prevention of
Migraine and Cluster Headache.
A
new or increasing headache may be a sign of an underlying medical problem, and needs to be evaluated prior to chronic
treatment for presumed
migraines.